Achaogen Inc (AKAO):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Achaogen Inc (AKAO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3390)・商品コード:DATA904C3390
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:53
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Achaogen Inc (Achaogen) is a biopharmaceutical company that discovers, develops and commercializes novel anti bacterials for the treatment of multi-drug resistant and gram-negative infections. The company offers plazomicin for the treatment of serious bacterial infections including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae. Its pipeline products include C-scape, novel aminoglycoside, and others. Achaogen’s C-Scape is a combination of an approved beta-lactam and an approved beta-lactamase inhibitor that can treat patients with complex urinary tract infections due to MDR pathogens. The company collaborates with antibacterial drug development companies and academic researchers in the field of antibiotic pharmacology. Achaogen is headquartered in San Francisco, California, the US.

Achaogen Inc (AKAO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achaogen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Achaogen Raises US$19 Million In Venture Financing 11
Partnerships 12
Achaogen Enters into Agreement with Microgenics 12
Licensing Agreements 13
Achaogen Enters into Licensing Agreement with Crystal Bioscience 13
Achaogen Enters into Licensing Agreement with Trianni 14
Equity Offering 15
Achaogen to Raise up to USD50 Million in Public Offering of Shares 15
Achaogen Raises USD112.5 Million in Public Offering of Shares 16
Achaogen to Raise USD10 Million in Private Placement of Shares 18
Achaogen Receives USD5.3 Million in Public Offering of Shares 19
Achaogen Raises USD101 Million in Public Offering of Shares 20
Achaogen Raises USD25 Million in Private Placement of Shares 22
Achaogen Completes IPO For US$82.8 Million 24
Achaogen Inc – Key Competitors 25
Achaogen Inc – Key Employees 26
Achaogen Inc – Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Financial Announcements 28
Aug 06, 2018: Achaogen reports second quarter 2018 financial results and provides corporate update 28
May 04, 2018: Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update 30
Feb 27, 2018: Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 31
Nov 08, 2017: Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33
Aug 03, 2017: Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update 34
May 08, 2017: Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update 36
Mar 14, 2017: Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 38
Corporate Communications 40
Dec 11, 2017: Achaogen Appoints Blake Wise Chief Executive Officer 40
Sep 18, 2017: Achaogen Adds Liz Bhatt as Chief Business Officer 41
Jul 13, 2017: Achaogen Appoints Dr. Karen Bernstein to its Board of Directors 42
Feb 27, 2017: Achaogen Adds Janet Dorling as Chief Commercial Officer 43
Feb 23, 2017: Achaogen Announces Leadership Promotions 44
Jan 05, 2017: Achaogen appoints new board member 45
Government and Public Interest 46
May 05, 2017: Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria 46
Product News 47
07/25/2017: Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections 47
Mar 01, 2017: Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company’s R&D Day 48
Clinical Trials 49
Jan 02, 2018: Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape 49
Sep 28, 2017: Achaogen Awarded up to $18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape 51
Jun 01, 2017: Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Achaogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achaogen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achaogen Raises US$19 Million In Venture Financing 11
Achaogen Enters into Agreement with Microgenics 12
Achaogen Enters into Licensing Agreement with Crystal Bioscience 13
Achaogen Enters into Licensing Agreement with Trianni 14
Achaogen to Raise up to USD50 Million in Public Offering of Shares 15
Achaogen Raises USD112.5 Million in Public Offering of Shares 16
Achaogen to Raise USD10 Million in Private Placement of Shares 18
Achaogen Receives USD5.3 Million in Public Offering of Shares 19
Achaogen Raises USD101 Million in Public Offering of Shares 20
Achaogen Raises USD25 Million in Private Placement of Shares 22
Achaogen Completes IPO For US$82.8 Million 24
Achaogen Inc, Key Competitors 25
Achaogen Inc, Key Employees 26

List of Figures
Achaogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achaogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Achaogen Inc (AKAO):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3390)販売に関する免責事項を必ずご確認ください。
★調査レポート[Achaogen Inc (AKAO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆